New ETF Book by Larry Connors - Click here to read more
Health officials said a shipment of 40,000 doses of GlaxoSmithKline's Pandermrix or D-Pan intramuscular vaccine arrived on Saturday night.
Vaccination will be done as per the UAE National Immunisation Plan, which will be rolled out after minor modifications by the end of the week or early next, health ministry sources said.
Haj pilgrims will be given top priority under the modified plan but it will be their choice whether or not to be vaccinated, one source said. Each vaccinated individual will be provided with an international vaccination certificate.
"Though the World Health Organisation recommends giving priority to healthcare workers and other people under the high risk category in the first round of vaccinations, we have modified the plan due to the Haj season," said the source.
The manufacturing company has promised to deliver a total of 900,000 doses in batches in 2009.
Dr Aly Ziwar, GlaxoSmithKline's Medical and Regulatory Director, Gulf and Near East, said delivery of the vaccine had been pushed through because of concerns of the health risks posed during Haj. "Yes, the vaccine has been delivered as priority for pilgrims," he said.
Saudi Arabia said on Monday it is to vaccinate all its residents attending the Haj.
Although earlier studies had pointed out the need for two doses of the vaccine to be given 21 days apart, a recent study has suggested that a single dose was giving an equally good response.
The UAE health ministry has been studying a dossier presented by the company on the safety of the drug, which has already been approved for use in the European Union. Today it is expected to make the formal announcements regarding the local registration of the drug.
However, before the immunisation process starts, the ministry will launch a multi-pronged campaign to spread awareness on the need for and safety of the vaccine.
"We will involve the media in spreading the message and will also keep them updated on what steps the ministry is taking," the ministry source said.
A number of medical personnel will be trained on administering the vaccine through mobile and fixed units at primary healthcare and mother and childcare centres, school health departments, preventive medicine departments in the country. The Dubai Health Authority has already fixed 13 primary healthcare centres for the vaccination, while GlaxoSmithKline is finalising talks to offer free training courses to the ministry staff in this regard.
Heads of departments in all medical districts will also be trained on safety, storage, adverse effects and appropriate waste disposal of the vaccine. The new head of the Technical Health Committee to Combat H1N1, Dr Mahmoud Fikri, refused to comment on the issue but promised future transparency with the media.
Saudi Arabia said it has received the first tranche of 11 million vaccine doses and authorities were to begin vaccinating hundreds of thousands of health and other haj workers, as well as domestic pilgrims, against swine flu from next week, Dr Ziad Memish, the assistant deputy health minister for preventive medicine, told AFP. "The priority is for local pilgrims," he said.
asmaalizain@khaleejtimes.ae
To see more of the Khaleej Times, or to subscribe to the newspaper, go to http://www.khaleejtimes.com. Copyright (c) 2009, Khaleej Times, Dubai, United Arab Emirates Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
